---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-146584"
form_type: "8-K"
ticker: "TCRX"
cik: "0001783328"
company_name: "TScan Therapeutics, Inc."
filed_at: "2023-05-17T23:59:59+00:00"
generated_at: "2026-06-14T22:32:24.268849+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# TScan reports preliminary Phase 1 data for TSC-100/101; TSC-101 advances to Dose Level 2

## Summary
- TSC-101 in high-risk MDS patient: 100% donor chimerism, no p53 mutation detected (sensitivity 0.01%), no DLTs.
- TSC-100 in T-cell ALL patient showed T cell expansion with activation markers on Day 7 post-infusion.
- Study advancing TSC-101 to Dose Level 2; RP2D and interim data expected by end of 2023.
- Two control patients with MDS had incomplete donor chimerism; one in early relapse.
- Phase 1 trial design includes three dose levels; second dose at DL2 and DL3 for both candidates.

## SEC filing metadata
- accession: 0001193125-23-146584
- form_type: 8-K
- ticker: TCRX
- cik: 0001783328
- company_name: TScan Therapeutics, Inc.
- filed_at: 2023-05-17T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783328/000119312523146584/0001193125-23-146584-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783328/000119312523146584/d490821d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-146584
- JSON: https://secwatch.observer/filing/0001193125-23-146584.json
- Plain text: https://secwatch.observer/filing/0001193125-23-146584.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.